The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral CH63 4JY, United Kingdom; Liverpool Head & Neck Centre, Department of Molecular and Clinical Cancer Medicine, University of Liverpool Cancer Research Centre, University of Liverpool, Liverpool L69 3BX, United Kingdom.
Head and Neck Unit, Aintree University Hospital NHS Foundation Trust, Longmoor Lane, Fazakerly, Liverpool L9 7AL, United Kingdom; Liverpool Head & Neck Centre, Department of Molecular and Clinical Cancer Medicine, University of Liverpool Cancer Research Centre, University of Liverpool, Liverpool L69 3BX, United Kingdom.
Br J Oral Maxillofac Surg. 2021 Oct;59(8):959-962. doi: 10.1016/j.bjoms.2020.08.059. Epub 2020 Aug 20.
Outcomes remain poor for patients presenting with locally-advanced oral cancers and it remains imperative to re-evaluate adjuvant therapies to provide improved outcomes, ideally without compromising on long-term quality of life. We present current available evidence that supports the use of immune checkpoint inhibitors (ICI) in squamous cell carcinoma (SCC) of the head and neck and discuss trials examining the integration of ICI into the locoregional management of such lesions that are resectable. We focus particularly on the Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in Oral cavity cancer (NICO) trial which is investigating the integration of neoadjuvant and adjuvant ICI into the treatment of resectable locally-advanced oral cavity cancers.
对于局部晚期口腔癌患者，其预后仍然较差，因此必须重新评估辅助治疗方法，以提供更好的疗效，同时尽量不影响长期生活质量。我们目前提供了支持免疫检查点抑制剂（ICI）在头颈部鳞状细胞癌（SCC）中的应用的现有证据，并讨论了检查ICI 整合到局部区域管理可切除此类病变的临床试验。我们特别关注新辅助和辅助纳武利尤单抗作为口腔癌的免疫检查点抑制（NICO）试验，该试验正在研究将新辅助和辅助ICI 整合到可切除的局部晚期口腔癌的治疗中。
